Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Rezolute, Inc. - Common Stock (NV)
(NQ:
RZLT
)
5.045
+0.635 (+14.40%)
Streaming Delayed Price
Updated: 3:26 PM EST, Dec 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rezolute, Inc. - Common Stock (NV)
< Previous
1
2
3
4
5
Next >
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
December 03, 2024
Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit demonstrated in Expanded Access Program
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
November 07, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences
November 05, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
September 19, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment
September 09, 2024
FDA lifts clinical hold on Rezolute's RZ358 for treating congenital hyperinsulinism, allowing U.S. participants in Phase 3 study. Enrollment expected to start in 2025 with topline data by mid-year.
Via
Benzinga
Exposures
Product Safety
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
September 09, 2024
Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences
August 27, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
August 05, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
July 31, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
June 27, 2024
Additional $6.7M in funding resulting in approximately $67M in gross proceeds
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
June 24, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 14, 2024
Via
Benzinga
Why Adobe Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
June 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 14, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
June 14, 2024
Pre-market stock movers are worth checking out on Friday as we dive into all of the biggest news moving shares this morning!
Via
InvestorPlace
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday
June 14, 2024
Via
Benzinga
RH Posts Mixed Q1 Results, Joins MSC Industrial Direct And Other Big Stocks Moving Lower In Friday's Pre-Market Session
June 14, 2024
Via
Benzinga
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
June 13, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
June 13, 2024
Via
Benzinga
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 12, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
June 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 05, 2024
Via
Benzinga
Rezolute to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Why Urban Outfitters Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
May 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 22, 2024
Via
Benzinga
Why Is Small-Cap Metabolic-Focused Rezolute Stock Trading Higher On Wednesday?
May 22, 2024
Rezolute announced topline results from the Phase 2 study of RZ402 for diabetic macular edema, showing significant improvements in macular edema and a favorable safety profile.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
May 22, 2024
Pre-market stock movers are worth checking out on Wednesday as we offer up all the latest news sending shares higher and lower this morning!
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.